Titan Pharmaceuticals (NASDAQ:TTNP) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a report released on Tuesday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Stock Up 11.2 %

Titan Pharmaceuticals stock opened at $3.87 on Tuesday. The business has a 50-day simple moving average of $3.68 and a two-hundred day simple moving average of $4.02. Titan Pharmaceuticals has a 52-week low of $3.03 and a 52-week high of $14.80. The company has a market cap of $3.54 million, a P/E ratio of -0.74 and a beta of 1.19.

Titan Pharmaceuticals (NASDAQ:TTNP) last announced its earnings results on Thursday, March 20th. The specialty pharmaceutical company reported ($0.85) EPS for the quarter.

Titan Pharmaceuticals Company Profile

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.